ACY-738
CAS No. 1375465-91-0
ACY-738( ACY738 | ACY 738 )
Catalog No. M11552 CAS No. 1375465-91-0
ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 53 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 159 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 438 | In Stock |
|
| 100MG | 582 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameACY-738
-
NoteResearch use only, not for human use.
-
Brief DescriptionACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.
-
DescriptionACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs; induces dramatic increase in α-tubulin acetylation in brain and stimulates mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model.Depression Preclinical.
-
In VitroACY-738 (2.5?μM) increases the acetylated (lysine 40) fraction of α-tubulin in RN46A-B14 cells. ACY-738 (10 μM) induces cell death comparable to LBH589 and FK228.
-
In VivoACY-738 (5?mg/kg) leads to significant increase in α-tubulin acetylation in whole-brain lysates. ACY-738 (50?mg/kg) fails to produce an enhancement of locomotor activity in WT mice tested in a home cage environment. ACY-738 (5 mg/kg) reaches a maximum plasma concentration of 1310 ng/mL at 0.0830 h following treatment. ACY-738 (5 mg/kg BW) alters BM B cell differentiation, but shows no significant effect on IgG and C3 deposition in NZB/W mice. ACY-738 (20 mg/kg) significantly attenuates the severity of proteinuria in NZB/W F1 mice. ACY-738 (5 mg/kg) shows a significant decrease in anti-dsDNA production in NZB/W mice as they aged. ACY-738 (5, 20 mg/kg) attenuates sera IL-1β production as the NZB/W mice aged. ACY-738 (5 mg/kg) significantly reduces glomerular IL-6 and IL-10 mRNA levels by more than 50% while treatment with 20 mg/kg ACY-738 reduced IL-6 and IL-10 mRNA to non-detectable levels.
-
SynonymsACY738 | ACY 738
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC6
-
Research AreaNeurological Disease
-
IndicationDepression
Chemical Information
-
CAS Number1375465-91-0
-
Formula Weight270.2866
-
Molecular FormulaC14H14N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C(C1=CN=C(NC2(C3=CC=CC=C3)CC2)N=C1)NO
-
Chemical Name5-Pyrimidinecarboxamide, N-hydroxy-2-[(1-phenylcyclopropyl)amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jochems J, et al. Neuropsychopharmacology. 2014 Jan;39(2):389-400.
2. Regna NL, et al. Clin Immunol. 2016 Jan;162:58-73.
3. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
molnova catalog
related products
-
Givinostat hydrochlo...
Givinostat hydrochloride is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.
-
HDAC-IN-52
HDAC-IN-52, a pyridine-containing HDAC inhibitor, effectively inhibits HDAC1, HDAC2, HDAC3, and HDAC10 with IC50 values of 0.189, 0.227, 0.440, and 0.446 μM, respectively.
-
SBHA
SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development.
Cart
sales@molnova.com